In an effort to increase access to select low-toxicity drugs by eliminating the costs associated with obtaining a physician's prescription, the Food and Drug Administration is considering a third classification, called behind-the-counter (BTC) drugs. These drugs would be available without a physician's prescription but, unlike over-the-counter (OTC) drugs, would not be freely available to patients. Rather, they would be available only in pharmacies and upon consultation with a pharmacist. Although the United States has limited experience with BTC drugs, other countries have introduced the BTC class, and their experiences can provide insight into the potential effects of this new class of drugs. The authors examine the potential effects of introducing BTC drugs by looking at experience with OTC drugs. The results of their analyses suggest that the introduction of BTC drugs in the United States could have varied effects in practice, and it is unclear whether such a policy would increase access to drugs, reduce medical costs, or increase health.
The research in this report was conducted by RAND Health and prepared for the Office of the Assistant Secretary for Planning and Evaluation,United States Department of Health and Human Services.
This report is part of the RAND Corporation working paper series. RAND working papers are intended to share researchers' latest findings and to solicit informal peer review. They have been approved for circulation by RAND but may not have been formally edited or peer reviewed.
Permission is given to duplicate this electronic document for personal use only, as long as it is unaltered and complete. Copies may not be duplicated for commercial purposes. Unauthorized posting of RAND PDFs to a non-RAND Web site is prohibited. RAND PDFs are protected under copyright law. For information on reprint and linking permissions, please visit the RAND Permissions page.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.